We are live on
!
Find out more
ACM
Atika Capital Management Portfolio holdings
AUM
$796M
1-Year Est. Return
167.57%
This Fund
S&P 500
This Quarter
Est. Return
+22.18%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$348M
AUM Growth
+$62.6M
(+22%)
Cap. Flow
+$45.9M
Cap. Flow
% of AUM
13.19%
Top 10 Holdings %
Top 10 Hldgs %
43.07%
Holding
103
New
27
Increased
20
Reduced
28
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$12.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$4M |
| 3 |
MZOR
Mazor Robotics Ltd.
MZOR
|
+$3.63M |
| 4 |
Albemarle
ALB
|
+$3.45M |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$4.67M |
| 2 |
Autodesk
ADSK
|
+$4.19M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$4.13M |
| 4 |
Zillow
Z
|
+$3.6M |
| 5 |
Shopify
SHOP
|
+$2.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.47% |
| 2 | Communication Services | 13.17% |
| 3 | Technology | 13.06% |
| 4 | Consumer Discretionary | 5.1% |
| 5 | Materials | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDCO
26
PUT
DELISTED
Medicines Co
MDCO
| $4.08M | 1.17% |
110,000
-90,300
| -45% | -$3.33M |
|
|
AVXS
27
DELISTED
AveXis, Inc. Common Stock
AVXS
| $3.97M | 1.14% |
41,000
+4,500
| +12% | +$406K |
|
|
28
Albemarle
ALB
$13.4B
| $3.95M | 1.14% |
+29,000
| New | +$3.45M |
|
29
CALL
American Airlines Group
AAL
$9.82B
| $3.9M | 1.12% |
82,000
| – | – |
|
30
Cognex
CGNX
$9.62B
| $3.86M | 1.11% |
70,000
+30,000
| +75% | +$1.52M |
|
31
Arista Networks
ANET
$199B
| $3.79M | 1.09% |
320,000
+88,000
| +38% | +$920K |
|
32
Baidu
BIDU
$35.7B
| $3.71M | 1.07% |
+15,000
| New | +$3.27M |
|
|
CALA
33
DELISTED
Calithera Biosciences, Inc
CALA
| $3.69M | 1.06% |
11,730
-1,270
| -10% | -$401K |
|
34
UnitedHealth
UNH
$382B
| $3.52M | 1.01% |
18,000
-3,500
| -16% | -$676K |
|
35
Amazon
AMZN
$2.44T
| $3.46M | 0.99% |
72,000
-28,000
| -28% | -$1.38M |
|
|
SIEN
36
DELISTED
Sientra, Inc.
SIEN
| $3.39M | 0.97% |
22,000
| – | – |
|
|
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.3M | 0.95% |
32,500
+10,500
| +48% | +$1.12M |
|
38
Vail Resorts
MTN
$5.7B
| $3.19M | 0.92% |
14,000
-300
| -2% | -$65.2K |
|
39
iRhythm Holdings
IRTC
$4.02B
| $3.19M | 0.92% |
+61,500
| New | +$2.78M |
|
40
CALL
Bristol-Myers Squibb
BMY
$129B
| $3.19M | 0.92% |
+50,000
| New | +$2.92M |
|
|
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.13M | 0.9% |
+58,000
| New | +$3.41M |
|
42
McDonald's
MCD
$193B
| $3.13M | 0.9% |
20,000
-400
| -2% | -$62.7K |
|
43
Floor & Decor
FND
$6.03B
| $3.11M | 0.89% |
80,000
-15,000
| -16% | -$557K |
|
|
ARNA
44
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.11M | 0.89% |
+122,000
| New | +$2.8M |
|
45
HDFC Bank
HDB
$123B
| $3.08M | 0.89% |
128,000
-12,000
| -9% | -$285K |
|
|
GIMO
46
DELISTED
Gigamon Inc.
GIMO
| $3.08M | 0.88% |
73,000
+43,000
| +143% | +$1.75M |
|
47
ICU Medical
ICUI
$4.16B
| $2.97M | 0.85% |
16,000
+2,000
| +14% | +$349K |
|
48
Alnylam Pharmaceuticals
ALNY
$38.3B
| $2.94M | 0.84% |
+25,000
| New | +$2.13M |
|
|
MDCO
49
DELISTED
Medicines Co
MDCO
| $2.89M | 0.83% |
78,000
-112,000
| -59% | -$4.13M |
|
50
Acadia Healthcare
ACHC
$2.52B
| $2.82M | 0.81% |
59,000
-32,000
| -35% | -$1.56M |
|
Similar funds
AGA
RIM
ACM
CAM
LSA
GWA
HP
Atika Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Atika Capital Management held 103 positions worth $348M, up 22% from $285M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Atika Capital Management deployed $45.9M of net new capital in Q3 2017, opening 27 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 100,000 shares worth $4.54M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 28% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the largest reduction was Autodesk, an estimated $4.19M trimmed.
- Atika Capital Management's largest Q3 2017 buy was Sarepta Therapeutics: 100,000 shares worth $4.54M.
- Atika Capital Management added most to Intuitive Surgical in Q3 2017, an estimated $12.3M increase.
- Atika Capital Management's biggest Q3 2017 reduction was Autodesk, cutting an estimated $4.19M.
- Atika Capital Management fully exited Regeneron Pharmaceuticals in Q3 2017, selling an estimated $4.67M.
- Atika Capital Management's ten largest holdings make up 43% of its $348M portfolio in Q3 2017.
- Atika Capital Management opened 27 new positions and closed 24 in Q3 2017.
- Atika Capital Management's portfolio value rose 22% quarter-over-quarter to $348M.
Based on Atika Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.